Phase 1 Trial of AMA1-C1/Alhydrogel plus CPG 7909: An Asexual Blood-Stage Vaccine for Plasmodium falciparum Malaria

Gregory E. D. Mullen, Ruth D. Ellis, Kazutoyo Miura et al. · 2008

Read Phase 1 Trial of AMA1-C1/Alhydrogel plus CPG 7909: An Asexual Blood-Stage Vaccine for Plasmodium falciparum Malaria by Gregory E. D. Mullen, Ruth D. Ellis, Kazutoyo Miura et al. (2008) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0002940.txt.

Description

Gregory Mullen, Ruth Ellis, Kazutoyo Miura and co-authors ran a first human trial of a malaria vaccine mix in 2008. The vaccine targets AMA1, a surface protein of the malaria parasite's blood stage, and pairs it with the adjuvant CPG 7909 to boost response. AMA1 was a leading blood-stage candidate.

This phase 1 trial in PLOS ONE tested safety and immune response for the AMA1 vaccine on Alhydrogel plus the new adjuvant. Phase 1 is the earliest human stage, focused on safety. Malaria vaccine research needs such careful steps, since blood-stage infection is what makes people ill.

Catalog record

CREATORGregory E. D. Mullen, Ruth D. Ellis, Kazutoyo Miura et al.
YEAR2008
COLLECTIONPAPERS
FORMATTXT
FILE SIZE52 KB
LICENSECreative Commons CC0 License
RIGHTSCC0
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0002940

Browse the full library · About the Tower of Babel